Viking Therapeutics ( (VKTX) ) has released its Q1 earnings. Here is a breakdown of the information Viking Therapeutics presented to its investors.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for metabolic and endocrine disorders, leveraging its expertise in metabolism to improve patient outcomes.
In its first quarter of 2025, Viking Therapeutics reported significant progress in its clinical pipeline and corporate developments. The company highlighted the upcoming Phase 3 trials for its subcutaneous VK2735 and the full enrollment of its Phase 2 VENTURE-Oral Dosing trial in obesity, with data expected later this year. Additionally, Viking secured a manufacturing agreement with CordenPharma to support the future commercialization of VK2735.
Key financial metrics for the quarter included a net loss of $45.6 million, up from $27.4 million in the same period last year, primarily due to increased research and development and general administrative expenses. Despite the loss, Viking maintains a strong cash position with $852 million in cash and short-term investments, ensuring continued support for its pipeline development.
Viking’s strategic announcements include the advancement of its dual amylin and calcitonin receptor agonist program, with an investigational new drug application planned for later this year. The company also emphasized the potential of its oral VK2735 formulation as a convenient treatment option for obesity, which could transition patients from subcutaneous to oral therapy seamlessly.
Looking ahead, Viking Therapeutics remains focused on advancing its clinical programs and leveraging its robust cash reserves to support ongoing research and development efforts. The company anticipates reporting further clinical data in the second half of 2025, which could provide additional insights into the efficacy and safety of its therapeutic candidates.